IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status

Abstract

Controlled trials indicate that in MG, LEMS, and DM, IVIg at a total dose of 2 g/kg is a highly useful therapy. Uncontrolled trials and case reports indicate benefit in many different clinical situations, but further clinical investigation is required.

Myasthenic crisis: Guidelines for prevention and treatment

“…This was noticeable in the growing number of publications dealing with its application both in acquired adult and juvenile MG and other antibody-mediated neuromuscular diseases such as Guillain-Barre syndrome (GBS), CIDP, Multifocal Motor Neuropathy (MMN) and dermatomyositis [17,21,29,30,33,[67][68][69][70][71]74]. The increased interest can be explained by a number of different factors such as the relative ease of administration compared to PE, and a relatively benign long-term side effect profile.…”

Myasthenia and related disorders of the neuromuscular junction

“…It is generally used as an adjuvant therapy in treatment-resistant patients80 Oral prednisolone has been used alone and in combination with azathioprine, and case reports have suggested benefit 77. More recently, a single case report has highlighted a beneficial response to rituximab in a non-paraneoplastic LEMS patient who had failed conservative therapy 81…”

IVIG therapy in neurological disorders of childhood

“…However, adjunctive immunomodulatory therapy is necessary in some patients. Efficacy of IVIG therapy for DM in adults has been reported in a randomized, double blind, placebo controlled clinical trial and in several observational studies [10,21].…”